Jennifer Low joined 23andMe in 2018 as Head of Therapeutics Development. She oversees the transition of potential therapeutics from 23andMe's research laboratories into clinical development studies. Jennifer has considerable drug development experience. She has been the Chief Medical Officer and Executive Vice President of Research and Development at Loxo Oncology where she oversaw the clinical development of Vitrakvi. Prior to that she was a Senior Group Director at Genentech, a member of the Roche Group, where she oversaw the Erivedge, Zelboraf, and Cotellic clinical development programs among many others. She received her undergraduate degree from Caltech, her MD and PhD degrees from Georgetown, and completed her internal medicine residency at the University of California Davis, her medical oncology fellowship at the National Cancer Institute. She has co-authored papers appearing in the New England Journal of Medicine and Science.
Recently, several unique partnerships for population sequencing studies have been launched. Various medical organizations and pharmaceutical and direct-to-consumer testing companies are included in these partnerships. The designed studies are expected to create new insights, identify new disease targets, and improve individualized patient care. In this session we will hear updates about several of these collaborative population studies to learn about the various opportunities created, the resulting benefits for each of the partners, and the challenges that need to be overcome in relation to data flow and data sharing.